

The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care[☆]

* Guidelines prepared by representatives of Australian & New Zealand Obesity Society (ANZOS), Australian Diabetes Society (ADS), Australian & New Zealand Metabolic and Obesity Surgery Society (ANZMOSS) and Royal Australian College of General Practitioners (RACGP).

* Corresponding author at: Metabolism & Obesity Service, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.

E-mail addresses: tania.markovic@sydney.edu.au (T.P. Markovic), j.proietto@unimelb.edu.au (J. Proietto), profjohndixon@gmail.com (J.B. Dixon), drgeorgiarigas@gmail.com (G. Rigas), drgarydeed@outlook.com (G. Deed), jeffrey.hamdorf@uwa.edu.au (J.M. Hamdorf), erica.bessell@sydney.edu.au (E. Bessell), nathalie.kizirian@sydney.edu.au (N. Kizirian), ceo@diabetessociety.com.au (S. Andrikopoulos), stephen.colagiuri@sydney.edu.au (S. Colagiuri).

<https://doi.org/10.1016/j.orcp.2022.08.003>

Received 11 October 2021; Received in revised form 2 April 2022; Accepted 5 August 2022

1871-403X/© 2022 The Authors. Published by Elsevier Ltd on behalf of Asia Oceania Association for the Study of Obesity. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article as: Tania P. Markovic, *Obesity Research & Clinical Practice*, <https://doi.org/10.1016/j.orcp.2022.08.003>

References

- [1] Australian Bureau of Statistics. National Health Survey: First Results, 2017–2018; 2018.
- [2] Price Waterhouse Cooper. Weighing the cost of obesity: a case for action, 2015.
- [3] Diabetes Prevention Program Research, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009;374(9702):1677–86.
- [4] NHMRC. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia; 2013.
- [5] Bouchard C, Tremblay A, Despres JP, Nadeau A, Lupien PJ, Theriault G, et al. The response to long-term overfeeding in identical twins. *N Engl J Med* 1990;322(21):1477–82.
- [6] Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. *N Engl J Med* 1990;322(21):1483–7.
- [7] Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature* 1997;387(6636):903–8.
- [8] Stunkard AJ, Sorensen TI, Hanis C, Teasdale TW, Chakraborty R, Schull WJ, et al. An adoption study of human obesity. *N Engl J Med* 1986;314(4):193–8.
- [9] Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. *Nat Genet* 1998;20(2):113–4.
- [10] Huypens P, Sass S, Wu M, Dyckhoff D, Tschop M, Theis F, et al. Epigenetic germline inheritance of diet-induced obesity and insulin resistance. *Nat Genet* 2016;48(5):497–9.
- [11] Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. *N Engl J Med* 1976;295(7):349–53.
- [12] Obesity Australia. Rethink Obesity: a media guide on how to report on obesity, 2015.
- [13] Fruh SM, Nadglowski J, Hall HR, Davis SL, Crook ED, Zlomke K. Obesity stigma and bias. *J Nurse Pract* 2016;12(7):425–32.
- [14] Markovic TP, Natoli SJ. Paradoxical nutritional deficiency in overweight and obesity: the importance of nutrient density. *Med J Aust* 2009;190(3):149–51.
- [15] National Health and Medical Research Council. Australian Guide to Healthy Eating, 2013 (<http://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating>).
- [16] National Health and Medical Research Council. Australian Dietary Guidelines. Canberra, 2013.
- [17] Hu T, Mills KT, Yao L, Demanelis K, Eloustaz M, Yancy Jr WS, et al. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. *Am J Epidemiol* 2012;176(Suppl 7): S44–54.
- [18] Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med* 2009;360(9):859–73.
- [19] Gudzone KA, Doshi RS, Mehta AK, Chaudhry ZW, Jacobs DK, Vakil RM, et al. Efficacy of commercial weight-loss programs: an updated systematic review. *Ann Intern Med* 2015;162(7):501–12.
- [20] Sumarithran P, Proietto J. Safe year-long use of a very-low-calorie diet for the treatment of severe obesity. *Med J Aust* 2008;188(6):366–8.
- [21] Astbury NM, Aveyard P, Nickless A, Hood K, Corfield K, Lowe R, et al. Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial. *BMJ* 2018;362:k3760.
- [22] Christensen P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, Martinez JA, Handjiev S, et al. Men and women respond differently to rapid weight loss: metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). *Diabetes Obes Metab* 2018;20(12):2840–51.
- [23] Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial. *Lancet* 2018;391(10120):541–51.
- [24] Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DIRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* 2019;7(5):344–55.
- [25] Proietto J. Obesity and weight management at menopause. *Aust Fam Physician* 2017;46(6):368–70.
- [26] Australian Government. Physical activity and exercise guidelines for all Australians, 2021 (<https://www.health.gov.au/health-topics/physical-activity-and-exercise-guidelines-for-all-australians>).
- [27] The Royal College of General Practitioners. Smoking, nutrition, alcohol, physical activity (SNAP): A population health guide to behavioural risk factors in general practice, 2nd edition, Melbourne, 2015.
- [28] Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. *Diabetes Obes Metab* 2010;12(10):876–82.
- [29] Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. *Br Med J* 1968;1(5588):352–4.
- [30] Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUENCE): a randomized, placebo-controlled, phase 3 extension study. *Am J Clin Nutr* 2012;95(2):297–308.
- [31] Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;27(1):155–61.
- [32] Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. *Diabetes Obes Metab* 2017;19(9):1233–41.

- [33] Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med* 2015;373(1):11–22.
- [34] Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016; 375(4):311–22.
- [35] Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. *Diabetes Obes Metab* 2018;20(3):734–9.
- [36] Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. *Pharmacol Res* 2014;84:1–11.
- [37] Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2010;376(9741):595–605.
- [38] Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. *Diabetes Care* 2013;36(12):4022–9.
- [39] Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. *Obes Rev J Int Assoc Study Obes* 2011;12(5):e338–47.
- [40] Neoh SL, Sumithran P, Haywood CJ, Houlihan CA, Lee FT, Proietto J. Combination phentermine and topiramate for weight maintenance: the first Australian experience. *Med J Aust* 2014;201(4):224–6.
- [41] O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet* 2018;392(10148):637–49.
- [42] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med* 2021; 384(11):989.
- [43] Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. *Diabetes Care* 2016;39(6):861–77.
- [44] W.H.O. Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363(9403): 157–63.
- [45] Piers LS, Rowley KG, Soares MJ, O'Dea K. Relation of adiposity and body fat distribution to body mass index in Australians of Aboriginal and European ancestry. *Eur J Clin Nutr* 2003;57(8):956–63.
- [46] Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. *Nat Rev Endocrinol* 2020;16(3): 177–89.
- [47] Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. *Curr Obes Rep* 2017;6(2):187–94.
- [48] Dixon JB, Egger GJ, Finkelstein EA, Kral JG, Lambert GW. 'Obesity paradox' misunderstands the biology of optimal weight throughout the life cycle. *Int J Obes* 2015;39(1):82–4.
- [49] Rasmussen KM, Yaktine AL (Eds.). *Weight gain during pregnancy: reexamining the guidelines. The National Academies Collection: Reports funded by National Institutes of Health.* Washington (DC) 2009.
- [50] Get Healthy New South Wales. *Weight gain during pregnancy, 2021* (http://www.gethealthynsw.com.au/assets/pdf/resources/GHS_Fact_Sheet_Weight_Gain_During_Pregnancy_online_Final.pdf).
- [51] Aills L, Blankenship J, Buffington C, Furtado M, Parrott J. ASMBMS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. *Surg Obes Relat Dis* 2008;4(5 Suppl):S73–108.
- [52] Grima M, Dixon JB. Obesity-recommendations for management in general practice and beyond. *Aust Fam Physician* 2013;42(8):532–41.
- [53] Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. *Endocr Pract* 2013;19(2): 337–72.
- [54] Welbourn R, Dixon J, Barth JH, Finer N, Hughes CA, le Roux CW, et al. NICE-accredited commissioning guidance for weight assessment and management clinics: a model for a specialist multidisciplinary team approach for people with severe obesity. *Obes Surg* 2016;26(3):649–59.
- [55] le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet* 2017;389(10077):1399–409.